A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 268
- Registration Number
- NCT04085185
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy
Phase 3
Recruiting
- Conditions
- Classic Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT04044222
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia
Phase 2
Completed
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- Biological: IBI306
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04031742
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Capital Medical University, Beijing, China
Study of IBI318 in Participants With Advanced Malignancies
Phase 1
Completed
- Conditions
- Advanced Malignancy
- Interventions
- Biological: IBI318
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 103
- Registration Number
- NCT03875157
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT03814291
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03815812
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
Phase 3
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 492
- Registration Number
- NCT03802240
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2021-01-22
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 595
- Registration Number
- NCT03794440
- Locations
- 🇨🇳
Hospital of Fudan University, Shanghai, Shanghai, China
A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas
Phase 1
Completed
- Conditions
- Advanced Malignancies
- Interventions
- Biological: IBI188
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03763149
- Locations
- 🇺🇸
START (South Texas Accelerated Research Therapeutics, LLC), San Antonio, Texas, United States
🇺🇸Thomas Jefferson Univerity, Philadelphia, Pennsylvania, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT03758001
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
© Copyright 2025. All Rights Reserved by MedPath